Status:
COMPLETED
CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will compare the efficacy and safety of 2 dosing regimens of oral CellCept administered as a component of standard immunosuppressive therapy in recipients of kidney transplants. The anticip...
Eligibility Criteria
Inclusion
- adult patients \>=18 years of age;
- recipients of a primary kidney transplant.
Exclusion
- positive for HIV-1, human T-cell leukemia/lymphoma virus-1 (HTLV-1), or hepatitis B surface antigen;
- positive for hepatitis C virus, with moderate or severe liver disease;
- active malignancy or history of malignancy, excluding skin cancer (basal or squamous cell) that has been adequately treated;
- need for maintenance corticosteroids for another condition.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT00788567
Start Date
June 1 2005
End Date
May 1 2008
Last Update
November 3 2015
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Edmonton, Alberta, Canada, T6G 2S2
2
Vancouver, British Columbia, Canada, V5Z 1M9
3
Vancouver, British Columbia, Canada, V6Z 1Y6
4
Halifax, Nova Scotia, Canada, B3H2Y9